| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00569153 | Prostatic Neoplasms | Drug: TAK-700 | Millennium Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2008-04-01 | 2016-03-04 |
| NCT01046916 | Prostate Cancer | Drug: TAK-700 | Millennium Pharmaceuticals, Inc. | Phase 2 | 2010-05-01 | 2016-03-04 |
| NCT01816048 | Prostatic Neoplasms|Prostate Cancer | Drug: TAK-700|Radiation: Fluorine F 18 Sodium Fluoride|Procedure: Positron Emission Tomography|Procedure: Computed Tomography | University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc. | Phase 2 | 2013-05-01 | 2016-06-27 |
| NCT01809691 | Prostate Cancer | Drug: TAK-700|Drug: Bicalutamide | Southwest Oncology Group|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) | Phase 3 | 2013-03-01 | 2017-02-23 |
| NCT01808040 | Post Menopausal, Hormone Receptor Positive Breast Cancer | Drug: TAK700 | University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc. | Phase 1 | 2012-11-01 | 2016-08-19 |
| NCT01084655 | Prostate Cancer | Drug: TAK-700|Drug: Docetaxel|Drug: Prednisone | Millennium Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2010-07-01 | 2016-03-04 |
| NCT01658527 | Prostate Cancer | Drug: Orteronel|Drug: Bicalutamide | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 2014-01-01 | 2016-06-09 |
| NCT01549951 | Prostate Cancer | Drug: Orteronel+Prednisone | Millennium Pharmaceuticals, Inc. | Phase 2 | 2012-05-01 | 2016-04-24 |
| NCT01866423 | Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer | Drug: orteronel|Other: laboratory biomarker analysis | University of Southern California|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. | Phase 2 | 2013-10-01 | 2016-04-06 |
| NCT02053311 | Prostate Cancer | Drug: Orteronel|Drug: Placebo | Swiss Group for Clinical Cancer Research | Phase 3 | 2014-06-01 | 2017-02-17 |
| NCT01990209 | Metastatic Breast Cancer | Drug: Orteronel | SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc. | Phase 2 | 2014-03-01 | 2016-10-04 |
| NCT01707966 | Prostate Cancer | Drug: Orteronel|Drug: Placebo | Swiss Group for Clinical Cancer Research | Phase 3 | 2012-09-01 | 2016-07-25 |
| NCT01666314 | Prostate Cancer | Drug: Orteronel|Drug: Orteronel Placebo|Drug: Prednisone | Millennium Pharmaceuticals, Inc.|Takeda | Phase 1|Phase 2 | 2012-09-01 | 2016-09-19 |
| NCT01546987 | Prostate Cancer | Drug: bicalutamide|Drug: buserelin|Drug: flutamide|Drug: goserelin acetate|Drug: leuprolide acetate|Drug: orteronel|Drug: triptorelin | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology | Phase 3 | 2012-05-01 | 2015-11-14 |
| NCT01193257 | Prostate Cancer | Drug: Orteronel + prednisone|Drug: Placebo + prednisone | Millennium Pharmaceuticals, Inc.|Takeda | Phase 3 | 2010-11-01 | 2017-01-16 |
| NCT02054793 | Prostate Cancer|Castration-resistant Prostate Cancer | Drug: Itraconazole|Drug: Orteronel | Emmanuel Antonarakis, MD|Millennium Pharmaceuticals, Inc.|Johns Hopkins University | Phase 1|Phase 2 | 2014-06-01 | 2014-07-22 |
| NCT01193244 | Prostate Cancer | Drug: Orteronel|Drug: Placebo|Drug: Prednisone | Millennium Pharmaceuticals, Inc. | Phase 3 | 2010-10-01 | 2016-07-13 |
